Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Complete title: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Research Study Number AAML1531
 
Principal Investigator Todd Cooper
 
Phase III

Research Study Description

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number AAML1531
 
Contact Doug Hawkins, MD
 
Telephone 206/526-2100
 
E-mail
 

Keywords: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Pediatric Cancers, Miscellaneous; Myelodysplastic Syndromes (MDS); Leukemia, Myeloid; Myeloproliferative Disorders (MPD); Preleukemia; Bone Marrow Diseases; Down Syndrome

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials